Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer

Greenhalgh J, McLeod C, Bagust A, Boland A, Fleeman A, Dundar Y, Oyee J, Dickson R, Davis H, Green J, McKenna E, Pearson M
Record ID 32011000930
English
Authors' recommendations: Following a revised economic analysis submitted by the manufacturer, the AC accepted that an ICER of £47,000 per QALY gained was most plausible. The AC also considered that maintenance treatment with pemetrexed fulfilled the end of life criteria. The guidance issued by NICE, on 20 June 2010, in TA190 as a result of the STA states that: People who have received pemetrexed in combination with cisplatin as first-line chemotherapy cannot receive pemetrexed maintenance treatment.1.1 Pemetrexed is recommended as an option for the maintenance treatment of people with locally advanced or metastatic non-small-cell lung cancer other than predominantly squamous cell histology if disease has not progressed immediately following platinum-based chemotherapy in combination with gemcitabine, paclitaxel or docetaxel.
Details
Project Status: Completed
URL for project: http://www.hta.ac.uk/erg/supplements/supplement1402.pdf#nameddest=article05
Year Published: 2010
URL for published report: http://www.hta.ac.uk/project/2171.asp
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: England, United Kingdom
MeSH Terms
  • Cost-Benefit Analysis
  • England
  • Neoplasm Metastasis
  • Pemetrexed
  • Wales
  • Antimetabolites, Antineoplastic
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms
Contact
Organisation Name: NIHR Health Technology Assessment programme
Contact Address: NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name: journals.library@nihr.ac.uk
Contact Email: journals.library@nihr.ac.uk
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.